Columbia researchers have engineered bacteria as personalized cancer vaccines that activate the immune system to specifically seek out and destroy cancer cells.
Physician-scientist Juanma Schvartzman is a firm believer that his curiosity-driven research on cell metabolism and its influence on cell identity will offer clues for better cancer treatments.
Combining a diabetes drug with a cancer drug not only kills aggressive bladder cancer cells in mice, but also turns remaining malignant cells into a more benign state.
Two Columbia University Medical Center faculty members were present today when President Obama provided details of the precision medicine initiative he announced during this year’s State of the Union address.
Azra Raza, an internationally known specialist in the blood disorder myelodysplastic syndrome, sees patients who travel from all over the country to receive the latest therapies and to participate in research studies for this relatively rare condition.
Richard D. Carvajal, MD, has been named director of the Experimental Therapeutics/Phase I program and melanoma service in medical oncology at NewYork-Presbyterian/Columbia University Medical Center, effective Nov. 1, 2014.
Daniel Seidman, author of “Smoke-Free in 30 Days,” will participate in a blogtalkradio show Nov. 17 in advance of this year’s Great American Smokeout on Nov. 20.
A CUMC study found that the use of generic aromatase inhibitors, which cost considerably less than their brand-name counterparts, increased treatment adherence by 50 percent.
Using an innovative algorithm, CUMC researchers have found that loss of a gene called KLHL9 is the driving force behind the most aggressive form of glioblastoma, the most common form of brain cancer.
The Herbert Irving Comprehensive Cancer Center is one of only two NCI-designated Comprehensive Cancer Centers in New York City and one of only three in New York State.